It’s now 9 months since IMU announced to opening of the Ph1 Oncarlytics/Blincyto Combination trial. At the time of the announcement IMU stated that Ovarian, Breast and melanoma patients had been treated. So at least three patients were dosed 9 months ago .
The trial was expected to recruit 52 patients. With at least 3 straight off the bat, just maybe recruitment is easy because of the big basket of metastatic solid tumors which can be included. This gives us hope that the numbers included in our first Data Cut might be a pleasant surprise to the upside.
We also know from there are no safety and toxicity issues..
This trial is the big one for shareholders. This is the technology that nobody else in the world has. And if you believe Yuman Fong he’s seeing results that are “better than he expected “
All we have to do is be patient. Just wait for the results.
https://hotcopper.com.au/posts/72836537/single
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.3¢ |
Change
0.002(18.2%) |
Mkt cap ! $97.07M | |||
| Open | High | Low | Value | Volume |
| 1.2¢ | 1.4¢ | 1.1¢ | $625.7K | 50.56M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 5795292 | 1.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.3¢ | 3258567 | 9 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |